Allen C Gao

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 27

Top Topics

Radical Prostatectomy

Prostate Cancer

Top Venues

Research square

Cancer research

This page only lists publications with an associated author ORCID identifier.

Publications

Bo Chen, Pengfei Xu, Joy C Yang, Christopher Nip, Leyi Wang, Yuqiu Shen, Shu Ning, Yufeng Shang, Eva Corey, Allen C Gao, Jason E Gestwicki, Qiang Wei, Liangren Liu, Chengfei Liu
Plexin D1 emerges as a novel target in the development of neural lineage plasticity in treatment-resistant prostate cancer. Oncogene 43 (30) (2024)
Bo Chen, Pengfei Xu, Joy C Yang, Christopher Nip, Leyi Wang, Yuqiu Shen, Shu Ning, Yufeng Shang, Eva Corey, Allen C Gao, Jason E Gestwicki, Qiang Wei, Liangren Liu, Chengfei Liu
Plexin D1 emerges as a novel target in the development of neural lineage plasticity in treatment-resistant prostate cancer. Oncogene 43 (30) (2024)
Shu Ning, Cameron M Armstrong, Enming Xing, Amy R Leslie, Richard Y Gao, Masuda Sharifi, Zachary A Schaaf, Wei Lou, Xiangrui Han, Desiree H Xu, Rui Yang, Jeffrey Cheng, Shabber Mohammed, Nicholas Mitsiades, Chengfei Liu, Alan P Lombard, Chun-Yi Wu, Xiaolin Cheng, Pui-Kai Li, Allen C Gao
LX1 Targets Androgen Receptor Variants and AKR1C3 to overcome Therapy Resistance in Advanced Prostate Cancer. Cancer research (2024)
Chengfei Liu, Bo Chen, Pengfei Xu, Joy C Yang, Christopher Nip, Leyi Wang, Yuqiu Shen, Shu Ning, Yufeng Shang, Eva Corey, Allen C Gao, Jason E Gestwicki, Qiang Wei, Liangren Liu
Plexin D1 emerges as a novel target in the development of neural lineage plasticity in treatment-resistant prostate cancer. Research square (2024)
Bo Chen, Pengfei Xu, Joy C Yang, Christopher Nip, Leyi Wang, Yuqiu Shen, Shu Ning, Yufeng Shang, Eva Corey, Allen C Gao, Jason E Gestwicki, Qiang Wei, Liangren Liu, Chengfei Liu
Plexin D1 emerges as a novel target in the development of neural lineage plasticity in treatment-resistant prostate cancer. Oncogene 43 (30) (2024)
Chengfei Liu, Bo Chen, Pengfei Xu, Joy C Yang, Christopher Nip, Leyi Wang, Yuqiu Shen, Shu Ning, Yufeng Shang, Eva Corey, Allen C Gao, Jason E Gestwicki, Qiang Wei, Liangren Liu
Plexin D1 emerges as a novel target in the development of neural lineage plasticity in treatment-resistant prostate cancer. Research square (2024)
Bo Chen, Pengfei Xu, Joy C Yang, Christopher Nip, Leyi Wang, Yuqiu Shen, Shu Ning, Yufeng Shang, Eva Corey, Allen C Gao, Jason E Gestwicki, Qiang Wei, Liangren Liu, Chengfei Liu
Plexin D1 emerges as a novel target in the development of neural lineage plasticity in treatment-resistant prostate cancer. Oncogene (2024)
Bo Chen, Pengfei Xu, Joy C Yang, Christopher Nip, Leyi Wang, Yuqiu Shen, Shu Ning, Yufeng Shang, Eva Corey, Allen C Gao, Jason E Gestwicki, Qiang Wei, Liangren Liu, Chengfei Liu
Plexin D1 emerges as a novel target in the development of neural lineage plasticity in treatment-resistant prostate cancer. Oncogene 43 (30) (2024)
Bo Chen, Pengfei Xu, Joy C Yang, Christopher Nip, Leyi Wang, Yuqiu Shen, Shu Ning, Yufeng Shang, Eva Corey, Allen C Gao, Jason E Gestwicki, Qiang Wei, Liangren Liu, Chengfei Liu
Plexin D1 emerges as a novel target in the development of neural lineage plasticity in treatment-resistant prostate cancer. Oncogene (2024)
Chengfei Liu, Bo Chen, Pengfei Xu, Joy C Yang, Christopher Nip, Leyi Wang, Yuqiu Shen, Shu Ning, Yufeng Shang, Eva Corey, Allen C Gao, Jason E Gestwicki, Qiang Wei, Liangren Liu
Plexin D1 emerges as a novel target in the development of neural lineage plasticity in treatment-resistant prostate cancer. Research square (2024)
Chengfei Liu, Bo Chen, Pengfei Xu, Joy C Yang, Christopher Nip, Leyi Wang, Yuqiu Shen, Shu Ning, Yufeng Shang, Eva Corey, Allen C Gao, Jason E Gestwicki, Qiang Wei, Liangren Liu
Plexin D1 emerges as a novel target in the development of neural lineage plasticity in treatment-resistant prostate cancer. Research square (2024)
Chengfei Liu, Bo Chen, Pengfei Xu, Joy C Yang, Christopher Nip, Leyi Wang, Yuqiu Shen, Shu Ning, Yufeng Shang, Eva Corey, Allen C Gao, Jason E Gestwicki, Qiang Wei, Liangren Liu
Plexin D1 emerges as a novel target in the development of neural lineage plasticity in treatment-resistant prostate cancer. Research square (2024)
Bo Chen, Pengfei Xu, Joy C Yang, Christopher Nip, Leyi Wang, Yuqiu Shen, Shu Ning, Yufeng Shang, Eva Corey, Allen C Gao, Jason E Gestwicki, Qiang Wei, Liangren Liu, Chengfei Liu
Plexin D1 emerges as a novel target in the development of neural lineage plasticity in treatment-resistant prostate cancer. Oncogene (2024)
Chengfei Liu, Bo Chen, Pengfei Xu, Joy C Yang, Christopher Nip, Leyi Wang, Yuqiu Shen, Shu Ning, Yufeng Shang, Eva Corey, Allen C Gao, Jason E Gestwicki, Qiang Wei, Liangren Liu
Plexin D1 emerges as a novel target in the development of neural lineage plasticity in treatment-resistant prostate cancer. Research square (2024)
Joy C Yang, Pengfei Xu, Shu Ning, Logan J Wasielewski, Hans Adomat, Sung Hee Hwang, Christophe Morisseau, Martin E Gleave, Eva Corey, Allen C Gao, Primo N Lara, Christopher P Evans, Bruce D Hammock, Chengfei Liu
Novel inhibition of AKR1C3 and androgen receptor axis by PTUPB synergizes enzalutamide treatment in advanced prostate cancer. Oncogene (2023)
Joy C Yang, Pengfei Xu, Shu Ning, Logan J Wasielewski, Hans Adomat, Sung Hee Hwang, Christophe Morisseau, Martin E Gleave, Eva Corey, Allen C Gao, Primo N Lara, Christopher P Evans, Bruce D Hammock, Chengfei Liu
Novel inhibition of AKR1C3 and androgen receptor axis by PTUPB synergizes enzalutamide treatment in advanced prostate cancer. Oncogene 42 (9) (2023)
Joy C Yang, Pengfei Xu, Shu Ning, Logan J Wasielewski, Hans Adomat, Sung Hee Hwang, Christophe Morisseau, Martin E Gleave, Eva Corey, Allen C Gao, Primo N Lara, Christopher P Evans, Bruce D Hammock, Chengfei Liu
Novel inhibition of AKR1C3 and androgen receptor axis by PTUPB synergizes enzalutamide treatment in advanced prostate cancer. Oncogene 42 (9) (2023)
Joy C Yang, Pengfei Xu, Shu Ning, Logan J Wasielewski, Hans Adomat, Sung Hee Hwang, Christophe Morisseau, Martin E Gleave, Eva Corey, Allen C Gao, Primo N Lara, Christopher P Evans, Bruce D Hammock, Chengfei Liu
Novel inhibition of AKR1C3 and androgen receptor axis by PTUPB synergizes enzalutamide treatment in advanced prostate cancer. Oncogene 42 (9) (2023)
Jinge Zhao, Sha Zhu, Ling Nie, Meng-Ni Zhang, Linmao Zheng, Nanwei Xu, Diming Cai, Xiaomeng Sun, Junru Chen, Jindong Dai, Yuchao Ni, Zhipeng Wang, Xingming Zhang, Jiayu Liang, Yuntian Chen, Xu Hu, Xiuyi Pan, Xiaoxue Yin, Haoyang Liu, Fengnian Zhao, Bei Zhang, Hao Chen, Jiashun Miao, Cong Qin, Xiaochen Zhao, Jin Yao, Zhenhua Liu, Banghua Liao, Qiang Wei, Xiang Li, Zhenhua Liu, Allen C Gao, Zhenlin Huang, Peng-Fei Shen, Ni Chen, Hao Zeng, Guangxi Sun
Genomic and Evolutionary Characterization of Concurrent Intraductal Carcinoma and Adenocarcinoma of the Prostate. Cancer research (2023)
Joy C Yang, Pengfei Xu, Shu Ning, Logan J Wasielewski, Hans Adomat, Sung Hee Hwang, Christophe Morisseau, Martin E Gleave, Eva Corey, Allen C Gao, Primo N Lara, Christopher P Evans, Bruce D Hammock, Chengfei Liu
Novel inhibition of AKR1C3 and androgen receptor axis by PTUPB synergizes enzalutamide treatment in advanced prostate cancer. Oncogene 42 (9) (2023)
Joy C Yang, Pengfei Xu, Shu Ning, Logan J Wasielewski, Hans Adomat, Sung Hee Hwang, Christophe Morisseau, Martin E Gleave, Eva Corey, Allen C Gao, Primo N Lara, Christopher P Evans, Bruce D Hammock, Chengfei Liu
Novel inhibition of AKR1C3 and androgen receptor axis by PTUPB synergizes enzalutamide treatment in advanced prostate cancer. Oncogene 42 (9) (2023)
Joy C Yang, Pengfei Xu, Shu Ning, Logan J Wasielewski, Hans Adomat, Sung Hee Hwang, Christophe Morisseau, Martin E Gleave, Eva Corey, Allen C Gao, Primo N Lara, Christopher P Evans, Bruce D Hammock, Chengfei Liu
Novel inhibition of AKR1C3 and androgen receptor axis by PTUPB synergizes enzalutamide treatment in advanced prostate cancer. Oncogene (2023)
Joy C Yang, Pengfei Xu, Shu Ning, Logan J Wasielewski, Hans Adomat, Sung Hee Hwang, Christophe Morisseau, Martin E Gleave, Eva Corey, Allen C Gao, Primo N Lara, Christopher P Evans, Bruce D Hammock, Chengfei Liu
Novel inhibition of AKR1C3 and androgen receptor axis by PTUPB synergizes enzalutamide treatment in advanced prostate cancer. Oncogene (2023)
Shu Ning, Chengfei Liu, Wei Lou, Joy C Yang, Alan P Lombard, Leandro S D'Abronzo, Neelu Batra, Ai-Ming Yu, Amy R Leslie, Masuda Sharifi, Christopher P Evans, Allen C Gao
Bioengineered BERA-Wnt5a siRNA Targeting Wnt5a/FZD2 Signaling Suppresses Advanced Prostate Cancer Tumor Growth and Enhances Enzalutamide Treatment. Molecular cancer therapeutics 21 (10) (2022)
Jing Wang, Jingjing Li, Lijuan Yin, Tianjie Pu, Jing Wei, Varsha Karthikeyan, Tzu-Ping Lin, Allen C Gao, Jason Boyang Wu
Neuropilin-2 promotes lineage plasticity and progression to neuroendocrine prostate cancer. Oncogene 41 (37) (2022)
Chengfei Liu, Cameron M Armstrong, Shu Ning, Joy C Yang, Wei Lou, Alan P Lombard, Jinge Zhao, Chun-Yi Wu, Ai-Ming Yu, Christopher P Evans, Clifford G Tepper, Pui-Kai Li, Allen C Gao
ARVib suppresses growth of advanced prostate cancer via inhibition of androgen receptor signaling. Oncogene 40 (35) (2021)
Cameron M Armstrong, Chengfei Liu, Wei Lou, Alan P Lombard, Christopher P Evans, Allen C Gao
MicroRNA-181a promotes docetaxel resistance in prostate cancer cells. The Prostate 77 (9) (2017)